Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 1.24. At the close of
Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares stood at 1.15 million during the last session, with the company’s beta value hitting 1.24. At the close of
In the last trading session, 1.16 million Stoke Therapeutics Inc (NASDAQ:STOK) shares changed hands as the company’s beta touched 1.24. With the company’s per share
Stoke Therapeutics Inc (NASDAQ:STOK) has a beta value of 1.09 and has seen 1.56 million shares traded in the last trading session. The company, currently
During the last session, Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares were 1.38 million, with the beta value of the company hitting 1.04. At the end
In the last trading session, 1.07 million shares of the Stoke Therapeutics Inc (NASDAQ:STOK) were traded, and its beta was 1.01. Most recently the company’s
Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares stood at 1.07 million during the last session, with the company’s beta value hitting 0.99. At the close of
In the latest trading session, 0.48 million Stoke Therapeutics Inc (NASDAQ:STOK) shares changed hands as the company’s beta touched 0.95. With the company’s most recent
In last trading session, Stoke Therapeutics Inc (NASDAQ:STOK) saw 0.88 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price
During the last session, Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares were 0.51 million, with the beta value of the company hitting 1.01. At the end
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
